Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Real world outcomes of patients with cold agglutinin disease

Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Robert Baker, Rajeev Gupta, Jindriska Lindsay, Charalampia Kyriakou, Shirley D'Sa

Blood (2025) 146 (Supplement 1): 4677.

https://doi.org/10.1182/blood-2025-4677

Published: 2025

Journal Articles

Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom

Blood (2025) 146 (Supplement 1): 4045.

https://doi.org/10.1182/blood-2025-4045

Published: 2025

Journal Articles

The use of MYD88 and IGH PCR in the diagnosis and follow up of Βing-neel syndrome

Ke Xu, June Hyun, Robert Baker, Evan Vitsaras, Nicole Japzon, Shiwen Koay, Jahanzaib Khwaja, Jindriska Lindsay, Charalampia Kyriakou, Michael Lunn, Rajeev Gupta, Shirley D'Sa

Blood (2025) 146 (Supplement 1): 5736.

https://doi.org/10.1182/blood-2025-5736

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Bing-Neel Syndrome - a Case Series of 46 Patients from the United Kingdom

Oliver M Tomkins, Jahanzaib Khwaja, Nicole Japzon, Shiwen Koay, Chandrashekar Hoskote, Charalampia Kyriakou, Jindriska Lindsay, Michael P Lunn, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2024-206989

Published: 2024

Journal Articles

Focal Symptomatic Bone Involvement with Waldenström's Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma

Oliver M Tomkins, Nicole Japzon, Jahanzaib Khwaja, Jindriska Lindsay, Charalampia Kyriakou, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2024-209771

Published: 2024

Journal Articles

Social Deprivation Affects Survival in Waldenström Macroglobulinaemia: Experience in the United Kingdom

Jahanzaib Khwaja, Oliver M Tomkins, Nicole Japzon, Jindriska Lindsay, Charalampia Kyriakou, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 7781.

https://doi.org/10.1182/blood-2024-207724

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Ethnic Disparities in Waldenström's Macroglobulinaemia in the United Kingdom - Analysis from the Wmuk Rory Morrison Registry

Blood (2021) 138 (Supplement 1): 1977.

https://doi.org/10.1182/blood-2021-153590

Published: 2021

Journal Articles

Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis

Oliver Tomkins, BMBS,MRCP, Jindriska Lindsay, FRCPath, Stephen Keddie, MRCP, Aisling Carr, PhDFRCP, Helen McCarthy, PhD FRCPath, Dima El-Sharkawi, MBBS, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Kirsty Cuthill, FRCPath,MBBS,MRCP,PhD, Guy Pratt, FRCPath, Ali Rismani, FRCPath, Michael P Lunn, Shirley D'Sa, MD FRCPath

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136558

Published: 2020

Journal Articles

Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Gulnaz Iqbal, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Richard Brouwer, BSc, Sherin Varghese, MSc, BA, Stephen Schey, MBBS, Jindriska Lindsay, FRCPath, Janet Dunn, PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140937

Published: 2020

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 1854.

https://doi.org/10.1182/blood.V130.Suppl_1.1854.1854

Published: 2017

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real world outcomes of patients with cold agglutinin disease

Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom

The use of MYD88 and IGH PCR in the diagnosis and follow up of Βing-neel syndrome

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Bing-Neel Syndrome - a Case Series of 46 Patients from the United Kingdom

Focal Symptomatic Bone Involvement with Waldenström's Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma

Social Deprivation Affects Survival in Waldenström Macroglobulinaemia: Experience in the United Kingdom

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Ethnic Disparities in Waldenström's Macroglobulinaemia in the United Kingdom - Analysis from the Wmuk Rory Morrison Registry

Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis

Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only